These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8824347)

  • 1. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
    Kunkel MW; Hook KE; Howard CT; Przybranowski S; Roberts BJ; Elliott WL; Leopold WR
    Invest New Drugs; 1996; 13(4):295-302. PubMed ID: 8824347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid carcinoma.
    Nelson JM; Fry DW
    Exp Cell Res; 1997 Jun; 233(2):383-90. PubMed ID: 9194500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H; Affleck K; Stubberfield C; Dean C
    Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
    Discafani CM; Carroll ML; Floyd MB; Hollander IJ; Husain Z; Johnson BD; Kitchen D; May MK; Malo MS; Minnick AA; Nilakantan R; Shen R; Wang YF; Wissner A; Greenberger LM
    Biochem Pharmacol; 1999 Apr; 57(8):917-25. PubMed ID: 10086326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Vincent PW; Bridges AJ; Dykes DJ; Fry DW; Leopold WR; Patmore SJ; Roberts BJ; Rose S; Sherwood V; Zhou H; Elliott WL
    Cancer Chemother Pharmacol; 2000; 45(3):231-8. PubMed ID: 10663641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
    Christensen JG; Schreck RE; Chan E; Wang X; Yang C; Liu L; Cui J; Sun L; Wei J; Cherrington JM; Mendel DB
    Clin Cancer Res; 2001 Dec; 7(12):4230-8. PubMed ID: 11751524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor.
    Faust RA; Tawfic S; Davis AT; Ahmed K
    Oral Oncol; 1999 May; 35(3):290-5. PubMed ID: 10621850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
    Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.
    Fry DW; Nelson JM; Slintak V; Keller PR; Rewcastle GW; Denny WA; Zhou H; Bridges AJ
    Biochem Pharmacol; 1997 Oct; 54(8):877-87. PubMed ID: 9354588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells.
    Korutla L; Kumar R
    Biochim Biophys Acta; 1994 Dec; 1224(3):597-600. PubMed ID: 7803521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Fry DW; Kraker AJ; McMichael A; Ambroso LA; Nelson JM; Leopold WR; Connors RW; Bridges AJ
    Science; 1994 Aug; 265(5175):1093-5. PubMed ID: 8066447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
    Wakeling AE; Barker AJ; Davies DH; Brown DS; Green LR; Cartlidge SA; Woodburn JR
    Breast Cancer Res Treat; 1996; 38(1):67-73. PubMed ID: 8825124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.